Vanguard Capital Management
CLRB icon

Vanguard Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Vanguard Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Buy
327,367
+245,483
+300% +$687K ﹤0.01% 3612
2026
Q1 		$208K Buy
+81,884
New +$264K ﹤0.01% 3793

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Vanguard Capital Management's CLRB Position: Q2 2026 in Review

Vanguard Capital Management increased its Cellectar Biosciences (CLRB) stake by 300% in Q2 2026, buying an estimated $687K and bringing the position to 327,367 shares worth $910K. The position accounts for ﹤0.01% of the portfolio, ranked #3612.

Vanguard Capital Management first reported a position in CLRB in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Vanguard Capital Management held 327,367 shares of Cellectar Biosciences worth $910K as of Q2 2026.
  • Vanguard Capital Management bought 245,483 Cellectar Biosciences shares in Q2 2026, an estimated $687K.
  • Cellectar Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3612 holding.
  • Vanguard Capital Management first reported a position in Cellectar Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.